Drug Information

Drug General Information
Drug ID
D0W8IY
Former ID
DIB007847
Drug Name
P-276
Synonyms
CDK4 inhibitor (cancer), Nicholas Piramal; P-276-00; P-664-02; CDK4 inhibitor (iv, cancer), Piramal Life Sciences; CDK4 inhibitor(iv, cancer), NPIL Research & Development
Drug Type
Small molecular drug
Indication Breast cancer [ICD9: 174, 175; ICD10:C50] Phase 2 [528734], [542849]
Company
Piramal Healthcare Ltd
Formula
C21H20ClNO5
InChI
InChI=1S/C21H20ClNO5/c1-23-7-6-12(14(23)10-24)19-15(25)8-16(26)20-17(27)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,14,24-26H,6-7,10H2,1H3/t12-,14+/m1/s1
InChIKey
QLUYMIVVAYRECT-OCCSQVGLSA-N
PubChem Compound ID
23643976
PubChem Substance ID
46526135, 56025308, 140770847, 223405963, 224384171, 226963074, 243945177, 249565617
Target and Pathway
Target(s) Cell division protein kinase 4 Target Info Inhibitor [531342]
Cell division control protein 2 homolog Target Info Inhibitor [528734]
KEGG Pathway Cell cycle
p53 signaling pathway
PI3K-Akt signaling pathway
Tight junction
T cell receptor signaling pathway
Hepatitis B
Measles
HTLV-I infection
Pathways in cancer
Viral carcinogenesis
Pancreatic cancer
Glioma
Melanoma
Bladder cancer
Chronic myeloid leukemia
Small cell lung cancer
Non-small cell lung cancerhsa04110:Cell cycle
Oocyte meiosis
Gap junction
Progesterone-mediated oocyte maturation
Herpes simplex infection
Epstein-Barr virus infection
NetPath Pathway TCR Signaling Pathway
EGFR1 Signaling Pathway
RANKL Signaling PathwayNetPath_21:RANKL Signaling Pathway
Pathway Interaction Database Regulation of nuclear SMAD2/3 signaling
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
Validated targets of C-MYC transcriptional activation
ATF-2 transcription factor network
FOXM1 transcription factor network
Regulation of retinoblastoma proteinp73pathway:p73 transcription factor network
E2F transcription factor network
PLK1 signaling events
AP-1 transcription factor network
Retinoic acid receptors-mediated signaling
Reactome Oxidative Stress Induced Senescence
Senescence-Associated Secretory Phenotype (SASP)
Oncogene Induced Senescence
RMTs methylate histone arginines
Transcriptional regulation of white adipocyte differentiation
Ubiquitin-dependent degradation of Cyclin D1
Cyclin D associated events in G1
Meiotic recombinationR-HSA-110056:MAPK3 (ERK1) activation
E2F mediated regulation of DNA replication
G0 and Early G1
Cyclin B2 mediated events
Golgi Cisternae Pericentriolar Stack Reorganization
Cdc20:Phospho-APC/C mediated degradation of Cyclin A
Regulation of APC/C activators between G1/S and early anaphase
Phosphorylation of the APC/C
Phosphorylation of Emi1
Condensation of Prophase Chromosomes
MASTL Facilitates Mitotic Progression
Resolution of Sister Chromatid Cohesion
Condensation of Prometaphase Chromosomes
Regulation of PLK1 Activity at G2/M Transition
Activation of NIMA Kinases NEK9, NEK6, NEK7
Loss of Nlp from mitotic centrosomes
Recruitment of mitotic centrosome proteins and complexes
Loss of proteins required for interphase microtubule organization?from the centrosome
Recruitment of NuMA to mitotic centrosomes
Depolymerisation of the Nuclear Lamina
Anchoring of the basal body to the plasma membrane
MAPK6/MAPK4 signaling
G1/S-Specific Transcription
Cyclin A/B1 associated events during G2/M transition
G2/M DNA replication checkpoint
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
WikiPathways DNA Damage Response
G1 to S cell cycle control
Ovarian Infertility Genes
PPAR Alpha Pathway
Bladder Cancer
S Phase
Transcriptional Regulation of White Adipocyte Differentiation
Meiotic Recombination
Retinoblastoma (RB) in Cancer
Spinal Cord Injury
Integrated Pancreatic Cancer Pathway
Prostate Cancer
Signaling Pathways in Glioblastoma
TSH signaling pathway
Integrated Breast Cancer Pathway
Integrated Cancer pathway
Mitotic G1-G1/S phases
Cell Cycle
miRNA Regulation of DNA Damage ResponseWP707:DNA Damage Response
TGF beta Signaling Pathway
MAP kinase activation in TLR cascade
RAF/MAP kinase cascade
Mitotic Prophase
Mitotic Prometaphase
BMI1
ATM Signaling Pathway
Regulation of Microtubule Cytoskeleton
Mitotic G2-G2/M phases
APC/C-mediated degradation of cell cycle proteins
Cell Cycle Checkpoints
miRNA Regulation of DNA Damage Response
References
Ref 528734P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.
Ref 542849(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7934).
Ref 528734P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.
Ref 531342Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.